Christopher Britten

Christopher Britten

Fortune : - $ au 31/05/2026

59 ans
Health Technology
Commercial Services
Finance

Profil

Christopher Jonathan Britten is currently Non-Executive Chairman at Thalia Therapeutics Plc since 2023.
He is Head-Mergers & Acquisitions at Neuraxpharm UK Ltd. He is Operations Manager at Avenue Machinery Corp.
Formerly, Dr. Britten was Non-Executive Director at Phico Therapeutics Ltd. He was Director-Life Sciences at Deloitte LLP (United Kingdom).
He was Managing Director at Torreya Partners (Europe) LLP.
He was Global Head-Mergers & Acquisitions at Sandoz AG.
He was Head-Business Development at Sanofi Pasteur MSD SNC.
He was Senior Vice President-Merges & Acquisitions at Advanz Pharma Corp.
Ltd.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
31/12/2024 0 ( -.--% ) - $ 31/05/2026

Postes actifs de Christopher Britten

SociétésPosteDébut
THALIA THERAPEUTICS PLC Président 01/08/2023
Corporate Officer/Principal -
Directeur des opérations -

Anciens postes connus de Christopher Britten

SociétésPosteFin
ADVANZ PHARMA CORP. LIMITED Corporate Officer/Principal 02/01/2022
Corporate Officer/Principal -
Corporate Officer/Principal -
Corporate Officer/Principal -
Corporate Officer/Principal -
Voir l'expérience en détail de Christopher Britten

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

11

Relations au 1er degré

9

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées9

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Distribution Services

  1. Bourse
  2. Insiders
  3. Christopher Britten